REFERENCES
1. Bruce AW, Chadwick P, Hassan A, VanCott GF. Recurrent urethritis in women. Can Med Assoc J 1973;108:973-6.
2. Reid G, Cook RL, Bruce AW. Examination of strains of lactobacilli for properties that may influence bacterial interference in the urinary tract. J Urol 1987;138:330-5.
3. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic
4. Reid G, Bruce AW, Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Available from: https://www.scienceopen.com/document?vid=496f67cb-83ec-4bcb-8f78-073ecc9eac75 [Last accessed on 16 Jan 2023].
5. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic
6. Reid G, Charbonneau D, Erb J, et al. Oral use of
7. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic
9. Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a
10. Miller AW, Penniston KL, Fitzpatrick K, Agudelo J, Tasian G, Lange D. Mechanisms of the intestinal and urinary microbiome in kidney stone disease. Nat Rev Urol 2022;19:695-707.
11. Schwaderer AL, Wolfe AJ. The association between bacteria and urinary stones. Ann Transl Med 2017;5:32.
12. Al KF, Denstedt JD, Daisley BA, et al. Ureteral stent microbiota is associated with patient comorbidities but not antibiotic exposure. Cell Rep Med 2020;1:100094.
13. Liu F, Zhang N, Wu Y, et al. The pelvis urinary microbiome in patients with kidney stones and clinical associations. BMC Microbiol 2020;20:336.
14. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015;13:269-84.
15. Subashchandrabose S, Mobley HLT. Virulence and fitness determinants of uropathogenic
16. Lewis AL, Gilbert NM. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect Dis 2020;8:Doc02.
17. Beerepoot MA, ter Riet G, Nys S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012;172:704-12.
18. Sadeghi-Bojd S, Naghshizadian R, Mazaheri M, Ghane Sharbaf F, Assadi F. Efficacy of probiotic prophylaxis after the first febrile urinary tract infection in children with normal urinary tracts. J Pediatric Infect Dis Soc 2020;9:305-10.
19. Wolff BJ, Price TK, Joyce CJ, Wolfe AJ, Mueller ER. Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial. Int Urol Nephrol 2019;51:2149-59.
20. Sarkissian CA, Alteri CJ, Mobley HLT. UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens. Vaccine 2019;37:4937-46.
21. Butler D, Ambite I, Wan MLY, Tran TH, Wullt B, Svanborg C. Immunomodulation therapy offers new molecular strategies to treat UTI. Nat Rev Urol 2022;19:419-37.
22. Wullt B, Butler DSC, Ambite I, Kinsolving J, Krintel C, Svanborg C. Immunomodulation-a molecular solution to treating patients with severe bladder pain syndrome? Eur Urol Open Sci 2021;31:49-58.
23. Biehl LM, Cruz Aguilar R, Farowski F, et al. Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection 2018;46:871-4.
24. Staley C, Vaughn BP, Graiziger CT, Sadowsky MJ, Khoruts A. Gut-sparing treatment of urinary tract infection in patients at high risk of
25. Li N, Yu H, Liu H, et al. Horizontal transfer of
26. Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes 2010;1:164-85.
27. Ouwehand AC, Forssten S, Hibberd AA, Lyra A, Stahl B. Probiotic approach to prevent antibiotic resistance. Ann Med 2016;48:246-55.
28. Kirjavainen PV, Laine RM, Carter DE, Hammond J-A, Reid G. Expression of anti-microbial defense factors in vaginal mucosa following exposure to Lactobacillus rhamnosus GR-1. Available from: https://ir.lib.uwo.ca/mnipub/270/ [Last accessed on 16 Jan 2023].
29. Abbasian B, Shair A, O'Gorman DB, et al. Potential role of extracellular ATP released by bacteria in bladder infection and contractility. mSphere 2019;4:e00439-19.
30. Stuivenberg GA, Chmiel JA, Akouris PP, Burton JP, Reid G. Probiotic bifidobacteria mitigate the deleterious effects of
31. Ali SN, Dayarathna TK, Ali AN, et al.
32. Macklaim JM, Gloor GB, Anukam KC, Cribby S, Reid G. At the crossroads of vaginal health and disease, the genome sequence of
33. Reid G, Millsap K, Bruce AW. Implantation of
34. Baker EP, Sayegh R, Kohler KM, et al. Evolution of host-microbe cell adherence by receptor domain shuffling. Elife 2022;11:e73330.
35. Puebla-Barragan S, Lamb B, Jafelice S, Reid G. Topical probiotics for women’s urogenital health: selection of an oil-based carrier. OBM Integrat Comp Med 2021;6:10.
36. Puebla-Barragan S, Reid G. Probiotics in cosmetic and personl care products: trends and challenges. Molecules 2021;26:1249.
37. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010;203:120.e1-6.
38. Petricevic L, Witt A. The role of
39. AEProbio. Clinical Guide to Probiotic Products Available in Canada. Available from: www.probioticchart.ca [Last accessed on 16 Jan 2023].
40. Dausset C, Bornes S, Miquel S, et al. Identification of sulfur components enhancing the anti-
41. Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microbiol 2007;73:179-85.
42. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
43. Wigner P, Bijak M, Saluk-Bijak J. Probiotics in the prevention of the calcium oxalate urolithiasis. Cells 2022;11:284.
44. Azcarate-Peril MA, Bruno-Barcena JM, Hassan HM, Klaenhammer TR. Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from
45. Watterson JD, Cadieux PA, Beiko DT, et al. Oxalate-degrading enzymes from
46. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021;21:226-240.
